ArticleFrontiers in oncology2026
Prognostic significance of CD56 expression in newly diagnosed multiple myeloma and its correlation with clinicopathological features.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the correlation of CD56 expression with clinical prognosis and adverse prognostic indicators in patients with newly diagnosed multiple myeloma (NDMM). Methods: We conducted a retrospective cohort study of 153 NDMM patients treated at Jiaozuo People's Hospital Affiliated to Henan Medical University between May 2014 and August 2024. Patients were stratified into the bortezomib cohort and the non-bortezomib cohort based on their treatment regimens, and were further divided into CD56 Results: No statistically significant differences in median progression-free survival (PFS) or overall survival (OS) were observed between the CD56 Conclusion: Bortezomib-based therapy may attenuate the adverse prognostic impact associated with CD56 deficiency. CD56 expression has prognostic significance in NDMM and is closely correlated with multiple adverse clinicopathological indicators; however, it does not serve as an independent prognostic factor for NDMM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.